A Leadership Transition at the International Myeloma Foundation
In a heartfelt announcement, the International Myeloma Foundation (IMF) recently shared the news that Mr. Yelak Biru will be stepping down from his role as President and CEO. After three years at the helm, Mr. Biru's departure marks the beginning of a new chapter for the organization.
Mr. Biru's Last Day with the IMF
Mr. Biru's tenure with the IMF will officially conclude on February 28, 2025. His decision to leave stems from a deep understanding of the need for fresh leadership to guide the IMF into its next phase. As he prepares to embrace new challenges, Mr. Biru’s contributions to myeloma advocacy will always be remembered.
Transformational Leadership and Impact
Under Mr. Biru's leadership, the IMF made remarkable strides in its mission to improve the lives of patients with multiple myeloma. His background as a myeloma patient advocate for over two decades provided him with a unique perspective, ensuring that patient voices were central to the foundation’s priorities. His influence touched every aspect of the organization, from research and education to patient support and advocacy.
A Vision for Myeloma Patients
One of Mr. Biru's most significant achievements was redefining the organization’s vision. This vision emphasizes a world where every myeloma patient can live life fully, free from the burdens of their disease. The priorities he helped set will continue to guide the IMF towards impactful initiatives, focusing on the needs of myeloma patients globally.
A Grateful Organization
IMF expresses profound gratitude to Mr. Biru for his tireless efforts in advancing the organization’s mission. His commitment has inspired both patients and healthcare providers alike. S. Vincent Rajkumar, MD, Chairperson of the IMF Board of Directors, highlighted the profound influence Mr. Biru has had on the foundation. His personal and professional dedication has led to significant advancements in myeloma care.
The Transition Process and Future Leadership
The IMF Board of Directors is committed to ensuring a smooth transition. In the wake of Mr. Biru's departure, they will begin the process of selecting a new CEO immediately, ensuring continuity in leadership. Martine Elias, CEO of Myeloma Canada, will play a pivotal role in this transition, bringing her extensive experience in guiding organizations through leadership changes.
Introducing Interim CEO Diane Moran
During this period of transition, Diane Moran, the IMF Senior Vice President of Strategic Planning, has been appointed as the Interim CEO. Having devoted nearly two decades to the IMF, Diane’s wealth of experience uniquely positions her to guide the organization forward. She expressed her honor in leading the IMF as it embarks on a transformative journey, further solidifying its commitment to improving the quality of life for myeloma patients.
Looking Ahead
As the IMF forges ahead, it will continue to prioritize innovation in myeloma treatment and care. The organization aims to empower patients and foster collaboration within the community, reinforcing its dedication to comprehensive support for myeloma patients worldwide.
About the International Myeloma Foundation
The International Myeloma Foundation, established in 1990, stands as the largest global foundation specifically focused on multiple myeloma. It encompasses an impressive network of over 525,000 members across 140 countries. The IMF is unwavering in its mission to enhance the quality of life for myeloma patients, advancing efforts toward a cure through focused initiatives in research, education, support, and advocacy. With numerous educational seminars and the establishment of the International Myeloma Working Group (IMWG), their impact continues to grow.
Frequently Asked Questions
Who is Mr. Yelak Biru?
Mr. Yelak Biru was President and CEO of the International Myeloma Foundation, stepping down after three impactful years.
What will happen after Mr. Biru's departure?
The IMF Board of Directors is in the process of selecting a new CEO while Diane Moran serves as the Interim CEO.
How has Mr. Biru contributed to the IMF?
Mr. Biru has significantly advanced research, education, patient support, and advocacy for myeloma patients during his tenure.
What is the mission of the IMF?
The IMF aims to improve the quality of life for myeloma patients while working towards prevention and discovery of a cure.
How can someone contact the IMF?
Individuals can reach the IMF at (800) 452-CURE (2873) or visit their website at www.myeloma.org.
